AstraZeneca has dumped billions into Brilinta R&D, but will it ever pay off?

AstraZeneca
AstraZeneca's Parthenon program for Brilinta has been a hit-and-miss affair despite $3.7 billion in R&D costs. (AstraZeneca)

With a series of late-stage trial readouts in the past few years, AstraZeneca has invested heavily in outcomes R&D for its stalwart clotbuster Brilinta. But there's big problem with that approach, which was once one of CEO Pascal Soriot's pet projects.

AstraZeneca may never see a return on investment for the billions it's dumped into the drug.

With an estimated $5.4 billion in sunk costs in Brilinta, AstraZeneca will likely never turn a profit on the blood thinner with generics expected to hit the market in 2024 and marketing costs swallowing up any increase in the drug's already disappointing sales, EvaluatePharma said Tuesday. 

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

Much of that R&D expense has been tied to AstraZeneca's Parthenon program, Evaluate reported, which has turned out a suite of trial data, including top-line results from the phase 3 Thales study released Monday. 

Parthenon—and its six outcomes trials for Brilinta—has already swallowed $3.7 billion in R&D costs with an additional $1.7 billion tied up in more than 80 investigator-sponsored trials, Evaluate said. Of the six Parthenon studies, two have led to label updates, while another two were called "clear failures" by Evaluate. 

RELATED: AstraZeneca dials back $3.5B Brilinta hopes after trial data fall short

"Companies risk these sums for the rewards of owning a life-saving drug, but it is hard to argue that in this case the spend was worth it," Evaluate said. 

In the most recent Parthenon trial––phase 3 Thales–– twice-daily Brilinta on top of aspirin significantly cut the risk of stroke or death over aspirin alone in patients who had suffered a stroke or transient ischemic attack and began treatment within 24 hours, according to top-line data released Monday. 

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.